High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial (2022)

Peer-Reviewed Study · Alemany A; Millat-Martinez P; Corbacho-Monné M; Malchair P; Ouchi D; Ruiz-Comellas A; Ramírez-Morros A; Rodríguez Codina J; Amado Simon R; Videla S; Costes G; Capdevila-Jáuregui M; Torrano-Soler P (and co-authors) · February 9, 2022

Alemany A et al., 2022-02-09: Multicentre double-blind placebo-controlled trial in 376 Catalonian outpatients given methylene blue-treated high-titre convalescent plasma: hospitalisation 12% vs 11% and no difference in viral load , a clean negative result for the plasma product.

Methylene blue-treated convalescent plasma did not prevent progression from mild to severe illness and did not reduce viral load in outpatients with COVID-19.

Abstract

Alemany A et al., 2022-02-09: Multicentre double-blind placebo-controlled trial in 376 Catalonian outpatients given methylene blue-treated high-titre convalescent plasma: hospitalisation 12% vs 11% and no difference in viral load , a clean negative result for the plasma product. Study type: multicentre, double-blind, randomised, placebo-controlled trial (NCT04621123), four centres, Catalonia, Spain. N=376 (188 plasma, 188 saline). Intervention: 250-300 mL methylene blue-treated convalescent plasma, single IV infusion; comparator 250 mL 0.9% saline. Coprimary endpoints: hospitalisation within 28 days (22 [12%] vs 21 [11%], RR 1.05) and viral load change to day 7 (-2.41 vs -2.32 log10). Stopped early because >85% of the target population had been vaccinated. Funding: Grifols and the YoMeCorono crowdfunding campaign (Grifols is a plasma-product manufacturer). Conflicts: 'We declare no competing interests.' Important: this tests MB-treated PLASMA, not methylene blue as a drug; it bears on the product class, not on oral/IV MB therapy. Study type: randomized trial.